Genomics News

• New Light Shed on HIV-1 Reservoir Reductions After Stem Cell Transplant Several factors underlie a profound reduction in the HIV-1 reservoir in patients who undergo allogeneic hematopoietic stem cell transplant (allo-HSCT) for hematologic disease, researchers report.
  Reuters Health Information, October 2018
• Urine Exosome Assay Could Curb Unnecessary Prostate Biopsies Exosome Diagnostics' ExoDx Prostate (IntelliScore) (EPI) urine exosome gene expression assay may help avoid unnecessary prostate biopsies, according to a large prospective study.
  Reuters Health Information, October 2018
• Scientists Use Stem Cells and Gene Editing to Make Mice With Two Mums Chinese scientists said on Thursday they had used gene editing and stem cell techniques to produce healthy mice with two mothers which developed well enough to go on to have normal offspring of their own.
  Reuters Health Information, October 2018
• PTEN Status Predicts Prostate Cancer Outcomes as Well as Multigene Panel PTEN loss by tumor immunohistochemistry (IHC) predicts prostate-cancer outcomes after radical prostatectomy as well as a commercial multigene panel does.
  Reuters Health Information, October 2018
• ALK Testing Rates Increasing in NSCLC Patients Testing for mutations in the ALK gene in patients with non-small-cell lung cancer (NSCLC) who are candidates for targeted therapy nearly doubled from 2011 to 2016, according to a new study in U.S. community practices.
  Reuters Health Information, October 2018
• Pathways to Rapid Wound Repair Open Door to Improved Healing Researchers have discovered why oral cavity wounds heal so rapidly. The findings may lead to more effective wound healing and less scaring in cutaneous wounds.
  Medscape Medical News, October 2018
• Genetics Drive Gout Risk Far More Than Diet The high serum urate levels associated with risk for gout are far more influenced by heredity than by diet, and experts suggested that recognizing this might increase the use of urate-lowering drugs.
  Medscape Medical News, October 2018
• Genetically Modified Pertussis Vaccine Produces Lasting Response Monovalent and combined acellular pertussis vaccines made with genetically inactivated toxin produce a stronger and more sustained antibody response than those containing chemically inactivated toxin, a new phase 2/3 trial shows.
  Reuters Health Information, October 2018
• ECNP 2018Promise of Precision Medicine in Psychiatry Nears Reality Innovative approaches and widespread data sharing are essential to develop novel therapies that deliver on the long-held promise of precision medicine in psychiatry, says a European expert.
  Medscape Medical News, October 2018
• African Women With Albinism Vow to Fight on After Kilimanjaro Climb
  Reuters Health Information, October 2018
• Alert FDA Approves Revcovi for Adenosine Deaminase SCID The US Food and Drug Administration has approved elapegademase-lvlr for the treatment of adults and children with adenosine deaminase severe combined immune deficiency.
  FDA Approvals, October 2018
• Bacterial DNA Sequencing Predicts Susceptibility to First-Line TB Drugs Sequencing bacterial DNA can predict drug resistance and susceptibility to first-line TB drugs, including isoniazid, rifampin, pyrazinamide and ethambutol, according to a new study.
  Reuters Health Information, October 2018
• TP53 Hotspot Mutations No More Oncogenic Than Others Common mutation points, or hotspots, in the tumor-suppressor gene TP53, the most frequently mutated gene in cancer, appear to be of no special significance in the disease process, according to studies in hundreds of human cell lines.
  Reuters Health Information, October 2018
• Chronic Allograft Injury Common Among Pediatric Liver-transplant Recipients A substantial proportion of pediatric liver-transplant patients with normal liver tests have varying degrees of subclinical chronic allograft injury, according to new findings.
  Reuters Health Information, September 2018
• Alnylam's Gene-Silencing Drug Shows Efficacy in Late-Stage Trial Alnylam Pharmaceuticals Inc said on Thursday its gene-silencing drug for a rare, painful genetic disease was found to be effective in a late-stage trial, putting the firm on track for a faster approval from U.S. regulator.
  Reuters Health Information, September 2018
• Variant Reclassification Common After Hereditary-Cancer Genetic Testing Many variants of uncertain significance (VUS) are upgraded to pathogenic or downgraded to benign after initial reporting of results from hereditary-cancer genetic testing, but three-quarters remain of uncertain significance years later, researchers report.
  Reuters Health Information, September 2018
• Malaria Mosquitoes Wiped Out in Lab Trials of Gene Drive Technique Scientists have succeeded in wiping out a population of caged mosquitoes in laboratory experiments using a type of genetic engineering known as a gene drive, which spread a modification blocking female reproduction.
  Reuters Health Information, September 2018
• Researchers Consider Ethics of Addressing Race in Biomedical Studies Three opinion essays published online Monday in a major medical journal address the ethics of addressing race in biomedical studies.
  Reuters Health Information, September 2018
• A Privacy Work-Around for Hereditary Cancer Testing When a patient has an inherited cancer-associated gene, it is desirable, but not easy, to have other family members tested. Using a commercial lab to circumvent nettlesome privacy regulations may help.
  Medscape Medical News, September 2018
• For HER2+ Breast Cancer, Anthracyclines and Trastuzumab Are Safer in Sequence Treating operable HER2-positive breast cancer with anthracyclines and trastuzumab in sequence works as well as giving them together, and it's safer, researchers suggest.
  Reuters Health Information, September 2018